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Background: Indigenous Australians have lower overall cancer survival which has not yet been fully explained. To
address this knowledge deficit, we investigated the associations between comorbidities, cancer treatment and
survival in Indigenous and non-Indigenous people in Queensland, Australia.
Methods: A cohort study of 956 Indigenous and 869 non-Indigenous patients diagnosed with cancer during
1998–2004, frequency-matched on age, sex, remoteness of residence and cancer type, and treated in Queensland
public hospitals. Survival after cancer diagnosis, and effect of stage, treatment, and comorbidities on survival were
examined using Cox proportional hazard models.
Results: Overall Indigenous people had more advanced cancer stage (p = 0.03), more comorbidities (p < 0.001), and
received less cancer treatment (77% vs. 86%, p = 0.001). Among patients without comorbidities and social
disadvantage, there was a lower uptake of treatment among Indigenous patients compared to non-Indigenous
patients. For those who received treatment, time to commencement, duration and dose of treatment were
comparable. Unadjusted cancer survival (HR = 1.30, 95% CI 1.15-1.48) and non-cancer survival (HR = 2.39, 95% CI
1.57-3.63) were lower in the Indigenous relative to non-Indigenous patients over the follow-up period. When
adjusted for clinical factors, there was no difference in cancer-specific survival between the groups (HR = 1.10,
95% CI 0.96-1.27). One-year survival was lower for Indigenous people for all-causes of death (adjusted HR = 1.33,
95% CI 1.12-1.83).
Conclusion: In this study, Indigenous Australians received less cancer treatment, had more comorbidities and had
more advanced cancer stage at diagnosis, factors which contribute to poorer cancer survival. Moreover, for patients
with a more favourable distribution of such prognostic factors, Indigenous patients received less treatment overall
relative to non-Indigenous patients. Personalised cancer care, which addresses the clinical, social and overall health
requirements of Indigenous patients, may improve their cancer outcomes.
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In Australia, cancer is the second leading cause of death
among Indigenous people, who continue to experience a
significantly lower life-expectancy than the population as
a whole. The observation of lower cancer survival among
Indigenous compared to non-Indigenous Australians is
well established [1-3] but not as yet fully explained.
Factors contributing to this survival disparity include later
stage of cancer at diagnosis, reduced uptake of or access
to treatment, high rates of case-fatal cancers and co-
morbidities, and language barriers [1,4,5]. A previous
study in the state of Queensland found that Indigenous
people with cancer were more likely to have comorbidi-
ties, to receive less treatment, and to experience worse
survival than non-Indigenous counterparts [6].
We replicated this earlier matched-cohort study design
where we compared Indigenous and non-Indigenous
people with cancer, this time including a larger cohort,
collecting more comprehensive and detailed information
on cancer treatment (e.g. timing to, type and amount of
treatment) and comorbidities. Here we examine the as-
sociations between comorbidities, cancer treatment and
survival among Indigenous and non-Indigenous cancer
patients in Queensland, the state with the second-largest
Indigenous population in Australia.
Methods
Methods for this comparative study of Indigenous and
non-Indigenous cancer patients are similar to those
described previously [6,7]. Briefly, all Indigenous adults
residing in the state of Queensland and diagnosed with
cancer during 1998–2004, identified through the popu-
lation-based Queensland Cancer Registry (QCR), were
eligible for inclusion. An equal number of non-Indigenous
cases were randomly identified from the Registry (fre-
quency-matched for age, sex, remoteness and cancer
type). All Australian residents have access to free public-
health care, including cancer treatment, and those with
private insurance, or the means to pay, can also access
treatment in the private sector [6]. We restricted our co-
hort to those who received the majority of treatment in a
Queensland public hospital, as about 98% of Indigenous
patients receive care in the public sector [8]. Patients
primarily treated elsewhere, those with missing health
records, or those treated in a hospital where regulatory
approval was not forthcoming, were excluded.
Clinical data (diagnostic details, cancer treatment, can-
cer stage, and presence of comorbidities), were abstracted
from medical records, as this information was not avail-
able from the QCR. Where records were insufficiently
detailed, further data were extracted from secondary pub-
lic hospitals’ records, to ensure that cancer treatment
and other clinical data were as complete as possible. In
general, details of surgery, chemotherapy or radiotherapytreatment that occurred outside the public hospital system
were documented in the public health records, through
treating clinician’s letters. Details on all comorbidities
recorded in the patients’ medical records were extracted;
comorbidities that fitted with the Charlson Comorbidity
Index Score (CCI) were included in the analysis. A modi-
fied CCI score (referred to here as ‘comorbidity score’)
was assigned based on severity and number of comorbid
conditions [9] and were grouped as: 0 (No known comor-
bidity), 1, 2+. Modification of the original CCI was neces-
sary where data on the severity of renal or liver disease
were not collected; these were classified as 2. Remoteness
(rurality of residence) was determined using the Accessi-
bility/Remoteness Index of Australia [10] with groups
ranging from 1 ‘highly accessible’ and 5 ‘very remote’.
For multivariate analysis, the categories were aggregated
to three groups; 1 (highly accessible and accessible), 2
(moderately accessible) and 3 (remote and very remote).
The Socio-Economic Index For Areas (SEIFA) was used
to classify place of residence into quintiles ranging from 1
‘most disadvantaged’ to 5 ‘most advantaged’ [11].
Cancer stage scores such as Tumour Nodes Metastasis
(TNM), Dukes and American Joint Committee on Cancer
(AJCC) [12] staging were converted to localised/regional/
distant spread. Treatment type (surgery, radiotherapy and
chemotherapy), intention (any intent, curative intent or
intention unknown), start date, duration, and quantity
(e.g. number of Gray (Gy), number of chemotherapy
cycles) were recorded. Date and cause of death were ob-
tained from the Australian National Death Index. All cases
were followed-up with respect to their vital status until
Dec 31, 2006.
Ethical approval was obtained from the Queensland
Health Department, health districts where data collec-
tion took place, and the Queensland Institute of Medical
Research.
Statistical methods
Pearson’s Chi-squared analysis or Fisher’s Exact test
were used for categorical data (proportions), t-test for
normally-distributed data (means), and non-parametric
tests (Kruskal-Wallis Test) for non-normally-distributed
data (medians). We estimated the relative risk of no treat-
ment associated with comorbidity by calculating the odds
ratios (OR) and 95% confidence interval (CI) using mul-
tivariate logistic regression analysis. Time to death was
assessed using Kaplan-Meier survival curves. The curves
were compared with the log-rank test statistic. Cox pro-
portional hazard modelling was used to calculate hazard
ratios (HRs) with associated 95% CI to assess the dif-
ferences between Indigenous and non-Indigenous cases
with respect to cancer survival (all-cause, cancer-specific
and non-cancer), after adjustment for cancer stage, co-
morbidities, socioeconomic status and treatment [13]. All
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Dec 31, 2006, whichever came sooner; cases who were still
alive at December 31, 2006 were censored at that date.
Results
The study included 956 Indigenous and 869 non-
Indigenous patients (368 cases were excluded). Clinical
data were abstracted from records at 44 hospitals.
Matching resulted in similar distribution of age, sex and
site of cancer diagnosis between the two groups. How-
ever, perfect matching for remoteness was not possible
as fewer non-Indigenous people with cancer lived in the
most remote locations at the time of diagnosis (Table 1).
Indigenous people were more likely to be socially
disadvantaged than their non-Indigenous counterparts
(p < 0.001) (Table 1).
Median time from presentation to diagnosis was 17 days
for both groups. Cancer stage was not recorded in the
clinical notes in approximately 10% of patients in both
groups; a further 3% of cases in each group were diag-
nosed with cancers for which a stage was not routinely
recorded (e.g. leukaemias, lymphomas). With these cases
excluded from analysis, fewer Indigenous people were di-
agnosed with local disease compared to non-Indigenous
people (38% vs. 45%, p = 0.03). There was no difference in
cancer stage among men (p = 0.65) but fewer Indigenous
women had localised cancer (41% vs. 51%), and 59% had
regional spread or distant metastasis compared to 48% for
non-Indigenous women (p = 0.007). Analysis, stratified by
remoteness, showed no difference in stage between Indi-
genous and non-Indigenous people from the same regions
(data not shown).
Indigenous patients were more likely to have comor-
bidities than their counterparts. They were significantly
less likely to have a zero comorbidity score and more
likely to have a score of 2 or greater (p < 0.001) (Table 1).
HbA1c, a measure of diabetes control [14], was included
if tested in the year prior to diagnosis or within 3 months
of diagnosis. Measurements were available for 40% of
Indigenous and 21% of non-Indigenous patients with
diabetes, with no difference in the proportion of cases
with HbA1c over 6.5%. Median measurements were
7.3% and 6.9% respectively, and were similar regardless
of sex or remoteness.
Indigenous cancer patients received less of any treat-
ment (75% vs. 86%, p < 0.001) and for those with non-
metastatic disease, received less treatment with curative
intent (Table 1). Irrespective of sex, stage, remoteness,
or socioeconomic status, Indigenous people received less
treatment (data not shown). Since matching was imper-
fect for place of residence (remoteness), in a sub-group
analysis we excluded people from the most remote re-
gions: Indigenous people from rural areas (77% vs. 89%,
p < 0.001) and those from more urban areas (83% vs.90%, p = 0.01) received less treatment (any, surgery,
chemotherapy or radiotherapy). Among patients who re-
ceived treatment, modes of curative cancer treatment
were similar (Figure 1). Indigenous people (n = 44) who
concurrently lived in cities, had no known comorbidity
and no metastatic cancer, and were not socially dis-
advantaged, took up or received less treatment than
non-Indigenous counterparts (n = 73) (82% vs. 95%,
p = 0.05) (Figure 2). Patients with diabetes and HbA1c
measurements greater than 6.5% received similar rates
of treatment (n = 62 (81%) vs. n = 9 (82%); p = 0.93) as
those without diabetes.
Being Indigenous increased the odds of not receiving any
cancer treatment and curative chemotherapy (Table 1).
Stratified analyses showed that among cases who had
no comorbidities recorded in the medical chart, being
Indigenous increased the likelihood of not taking up or re-
ceiving any cancer treatment and curative surgery; that was
also true among cases who had a comorbidity score of one.
The median time from date of diagnosis to the first can-
cer treatment was 14 days for Indigenous (n = 698) and
12 days for non-Indigenous people (n = 734; p = 0.20).
There was no significant difference in the median number
of days to first surgical treatment, chemotherapy or radio-
therapy between the two groups. For cases without meta-
static disease, there was no difference between Indigenous
and non-Indigenous people in the duration or quantity of
radiotherapy (52.5 Gy respectively) or number of cycles of
chemotherapy administered (p = 0.93). Also, there was no
difference in the proportion of people with non-metastatic
cancer who completed chemotherapy (76% of Indigenous
patients and 80% of non-Indigenous patients completed
chemotherapy regimen; p = 0.53) (Table 2).
Compared to non-Indigenous patients, the unadjusted
difference in overall survival was 37% worse for Indigenous
patients over the study period (Figure 3). Cancer-specific
survival and non-cancer survival were also significantly
lower (Table 3). The differential cancer-specific survival did
not remain significant after adjusting for demographic and
clinical factors, but persisted for non-cancer survival. Over-
all survival was 60% lower for Indigenous people in the first
year after diagnosis, but not significantly different in
subsequent years. The survival differential persisted after
adjustment for demographic factors, stage, comorbidities,
and treatment reduced the hazard ratio for the first year
(aHR = 1.33 95% CI 1.12-1.83), but not for subsequent
years. Overall, survival for Indigenous people who received
treatment was lower than for non-indigenous counterparts
(aHR = 1.26 95% CI 1.07-1.5), whereas survival was similar
for those who did not receive treatment (Figure 3).
Discussion
Compared with non-Indigenous patients resident in
Queensland, Australia, Indigenous people were diagnosed
Table 1 Demographic and clinical characteristics, and
patterns of care among Indigenous and non-indigenous
cancer patients, Queensland, Australia 1998–2004
Indigenous
(n = 956)
N (%)
Non-Indigenous
(n = 869)
N (%)
P-value
Age
18- 39 years 108 (11) 91 (11) 0.852
40 – 59 years 421 (44) 387 (45)
60 + years 427 (45) 391 (45)
Sex
male 436 (46) 393 (45) 0.870
female 520 (54) 476 (55)
Area of remoteness index
Highly accessible/Accessible 329 (34) 369 (43) <0.001
Moderately accessible 370 (39) 325 (37)
Remote/Highly remote 257 (27) 175 (20)
Socioeconomic status
(SEIFA)
1 Most disadvantaged 354 (37) 215 (25) <0.001
2 Disadvantaged 238 (25) 261 (30)
3 Intermediate advantage 213 (22) 219 (25)
4 Advantaged 111 (12) 136 (16)
5 Most advantaged 39 (4) 36 (4)
Cancer stage at diagnosis*
Localised cancer 316 (38) 336 (45) 0.030
Regional Spread 240 (29) 197 (26)
Distant metastasis 275 (33) 221 (29)
Unknown or not applicable 125 115
Comorbidity score**
0 481 (50) 601 (69) <0.001
1 256 (27) 143 (16)
2+ 219 (23) 125 (14)
Diabetes
No 669 (70) 785 (90) <0.001
Yes 287 (30) 84 (10)
HbA1C levels recorded (N = 113) (N = 18)
Equal to or less than 6.5% 36 (32) 7 (39) 0.485
Greater than 6.5% 77 (68) 11 (61)
Any cancer treatment
Given treatment 716 (75) 745 (86) <0.001
No treatment or treatment
unknown
240 (25) 124 (14)
Curative cancer treatment£ N = 556 N = 533
Given treatment 400(72) 417 (78) 0.030
No treatment or treatment
unknown
153 (28) 116 (22)
Table 1 Demographic and clinical characteristics, and
patterns of care among Indigenous and non-indigenous
cancer patients, Queensland, Australia 1998–2004
(Continued)
Surgery
Surgery 494 (52) 549 (64) <0.001
No surgery or treatment
unknown
462 (48) 320 (36)
Chemotherapy
Chemotherapy 269 (28) 321 (37) <0.001
No chemotherapy or
treatment unknown
687 (72) 548 (63)
Chemotherapy completed^ N = 160 N = 190
Completed 122 (76) 152 (80) 0.530
Not completed or treatment
unknown
38 (24) 38 (20)
Radiotherapy
Radiotherapy 325 (34) 359 (41) 0.001
No Radiotherapy or not sure 631 (66) 510 (59)
Age
18- 39 years 108 (11) 91 (11) 0.852
40 – 59 years 421 (44) 387 (45)
60 + years 427 (45) 391 (45)
Sex
male 436 (46) 393 (45) 0.870
female 520 (54) 476 (55)
Area of remoteness index
Highly accessible/Accessible 329 (34) 369 (43) <0.001
Moderately accessible 370 (39) 325 (37)
Remote/Highly remote 257 (27) 175 (20)
Socioeconomic status
(SEIFA)
1 Most disadvantaged 354 (37) 215 (25) <0.001
2 Disadvantaged 238 (25) 261 (30)
3 Intermediate advantage 213 (22) 219 (25)
4 Advantaged 111 (12) 136 (16)
5 Most advantaged 39 (4) 36 (4)
Cancer site and IDC code#
Bronchus and lung
(C33- C34)
187 (20) 173 (20) 0.9
Breast (C56) 111 (12) 107 (12)
Colorectal and small intestine
(C17-20)
87 (9) 89 (10)
Head and neck (C00- C14) 83 (9) 84 (10)
Lymphoma and leukaemia
(C42 & C77/ M 01- M10)
61 (6) 55 (6)
Cervix (C53) 56 (6) 49 (6)
Liver (C22) 48 (5) 30 (4)
Other cancers 41 (4) 32 (4)
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Table 1 Demographic and clinical characteristics, and
patterns of care among Indigenous and non-indigenous
cancer patients, Queensland, Australia 1998–2004
(Continued)
Renal tract (C64- C67) 40 (4) 46 (5)
Corpus uteri (C54) 38 (4) 36 (4)
Oesophagus (C15) 31 (3) 21 (2)
Other cancers 47 (5) 35 (4)
Ovary (C56) 29 (3) 29 (3)
Unknown primary (C80) 29 (3) 17 (2)
Stomach (16) 27 (3) 23 (3)
Prostate (C61) 25 (3) 17 (2)
Pancreas (C25) 22 (2) 25 (3)
Thyroid (C73) 21 (2) 14 (2)
Central Nervous System (C71) 13 (1) 12 (1)
Melanoma (C44 or M12)) 7 (1) 10 (1)
Cancer stage at diagnosis*
Localised cancer 316 (38) 336 (45) 0.030
Regional Spread 240 (29) 197 (26)
Distant metastasis 275 (33) 221 (29)
Unknown or not applicable 125 115
Comorbidity score**
0 481 (50) 601 (69) <0.001
1 256 (27) 143 (16)
2+ 219 (23) 125 (14)
Diabetes
No 669 (70) 785 (90) <0.001
Yes 287 (30) 84 (10)
HbA1C levels recorded (N = 113) (N = 18)
Equal to or less than 6.5% 36 (32) 7 (39) 0.485
Greater than 6.5% 77 (68) 11 (61)
Any cancer treatment
Given treatment 716 (75) 745 (86) <0.001
No treatment or treatment
unknown
240 (25) 124 (14)
Curative cancer treatment£ N = 556 N = 533
Given treatment 400 (72) 417 (78) 0.030
No treatment or treatment
unknown
153 (28) 116 (22)
Surgery
Surgery 494 (52) 549 (64) <0.001
No surgery or treatment
unknown
462 (48) 320 (36)
Chemotherapy
Chemotherapy 269 (28) 321 (37) <0.001
No chemotherapy or
treatment unknown
687 (72) 548 (63)
Table 1 Demographic and clinical characteristics, and
patterns of care among Indigenous and non-indigenous
cancer patients, Queensland, Australia 1998–2004
(Continued)
Chemotherapy
completed^
N = 160 N = 190
Completed 122 (76) 152 (80) 0.530
Not completed or treatment
unknown
38 (24) 38 (20)
Radiotherapy
Radiotherapy 325 (34) 359 (41) 0.001
No Radiotherapy or
treatment unknown
631 (66) 510 (59)
#International Classification of Diseases 10th Revision (ICD-10-AM) code.
*Cases with missing data not included in analysis but numbers presented
for completeness.
**Charlson Comorbidity Index: scores 2–5 and 5+ were grouped.
£Includes cases with localised and regional stage disease only.
^Includes only cases with non-metastatic disease who received chemotherapy.
Moore et al. BMC Cancer 2014, 14:517 Page 5 of 9
http://www.biomedcentral.com/1471-2407/14/517with more advanced cancer, had greater comorbidity,
received less cancer treatment and were 30% more likely to
die of their cancer; findings similar to those reported
previously [5,6,15]. Concomitant disease is reported to in-
fluence cancer treatment choices (dose, duration, modality),
cause complications, and impede survival [9,16-18]. Ex-
cess comorbidities have been shown to contribute to
lower curative treatment rates and poorer cancer survival
for New Zealand Māori [18,19], and contributed to the
survival disparity among Indigenous people with lung
cancer in Queensland [20]. Indigenous people with lung
cancer and diabetes had reportedly 40% worse survival
than Indigenous people without diabetes, whereas the
presence of diabetes was unrelated to survival in non-
Indigenous people [21].
In this study, stratified analysis showed that among
cases without comorbidity, being Indigenous was asso-
ciated with not receiving any cancer treatment, including
curative surgery. This suggests that factors other than or
in conjunction with comorbidity status may play a role. Of
particular concern are the reasons why Indigenous people
without comorbidities, who lived in an urban setting
where cancer services are easily accessible, were not so-
cially disadvantaged, and had localised cancer at diagnosis,
did not have treatment. Better identification of reasons for
treatment disparities in this group may enable cancer care
providers to increase treatment uptake and in turn im-
prove overall survival. Despite thorough review, we found
that reasons for not receiving treatment were not rou-
tinely documented in the medical charts. We thus recom-
mend that the views of patients and health services
personnel are sought and documented to elicit and
analyse barriers to treatment for Indigenous people. Our
study was unable to capture sufficient information re-
garding comorbidities not included in the Charslon
Figure 1 Comparison of mode of treatment received by Indigenous and non-Indigenous cancer patients (p = 0.910). *metastatic cases
excluded.
Table 2 Odds of receiving treatment in Indigenous
compared to non-Indigenous (referent group) cancer
patients: all cases and stratified by comorbidity score^
Adjusted OR* (95% CI)
Any treatment 0.46 (0.41, 0.63)
Stratified by: comorbidity score 0 0.36 (0.23, 0.57)
comorbidity score 1 0.43 (0.23, 0.81)
comorbidity score 2+ 0.73 (0.39, 1.34)
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tors which might preclude cancer treatment.
Our findings regarding treatment parallel reports from
a number of international [22-24] and local [6,25-27]
studies. We found that irrespective of remoteness or so-
cioeconomic advantage, Indigenous people received less
treatment than non-Indigenous counterparts (including
Indigenous people who were most advantaged). Factors
such as miscommunication and social and cultural
differences between patients and health care providers
[28,29], poor understanding of medical advice [30], in-
herent racism in the health system [31], lack of transportFigure 2 Time from diagnosis to all-cause death for Indigenous
and non-Indigenous people with cancer, adjusted for age, sex,
cancer site, place of residence (ARIA), socioeconomic (SEIFA),
comorbidity score (CCI), stage at diagnosis, treatment (follow-up
until 31st Dec 2006).
Curative treatment # 0.74 (0.56, 1.00)
Stratified by: comorbidity score 0 0.76 (0.46, 1.03)
comorbidity score 1 0.55 (0.28, 1.09)
comorbidity score 2+ 1.29 (0.65, 2.55)
Curative surgery # 0.82 (0.62,1.07)
Stratified by: comorbidity score 0 0.68 (0.48, 0.97)
comorbidity score 1 0.86 (0.46, 1.60)
comorbidity score 2+ 1.49 (0.74, 2.91)
Curative chemotherapy # 0.72 (0.53, 098)
Stratified by: comorbidity score 0 0.79 (0.55, 1.13)
comorbidity score 1 0.62 (0.30, 1.28)
comorbidity score 2+ 0.36 (0.12, 1.07)
Curative radiotherapy # 0.82 (0.63, 1.07)
Stratified by comorbidity score 0 0.88 (0.64), 1.23)
comorbidity score 1 0.56 (0.29, 1.08)
comorbidity score 2+ 0.66 (0.31, 1.42)
*Adjusted for age, sex, remoteness, socioeconomic status, stage, comorbidity
score.
# metastatic cases excluded.
^Comorbidity Score: 0 (no known comorbidity), 1 (Charlson index of 1) or
2+ (Charlson index of 2 or more).
Figure 3 Time from diagnosis to all-cause death for Indigenous and non-Indigenous people with respect to treatment, adjusted for
age, sex, cancer site, place of residence (ARIA), socioeconomic (SEIFA), comorbidity score (CCI), stage at diagnosis, treatment (Follow-up
until 31st Dec 2006).
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support persons [34], have been cited as some of the
reasons for treatment disparity. We found no delay for
patients receiving treatment in public hospitals, in con-
trast to earlier studies which reported a significant dif-
ference in time to surgery [6] and delays in treatment
[18,35]. We also report that the presence of diabetes or
elevated HbA1C did not influence treatment uptake and
that chemotherapy completion rates for those receiving
treatment for non-metastatic cancer, were similar for
both groups.
A greater proportion of Indigenous people in our
cohort had died before the end of the follow-up period,
and they were twice as likely to have died from a non-
cancer death. These results are consistent with the poor
cancer survival and higher mortality that have been
reported for Indigenous people with cancer elsewhere
[36-39]. Unadjusted analysis indicated a lower survivalTable 3 Proportional hazard ratios, using Cox regression mod
1998 and 2004, for Indigenous compared to non-Indigenous
HR
All cause death 1.37
Non-cancer death 2.39
Cancer death 1.30
Time to death (all causes) by years: 0 – 1 yr 1.60
1 – 2y 0.98
2- 3 yr 0.98
3- 4 yr 0.97
4- 5 yr 1.05
*Adjusted for: Sex, Age, Comorbidity Score (Modified Charlson Comorbidity Index):
Accessible 2 = Moderately accessible 3 = Remote/Highly remote; SEIFA (Socioeconom
3 =Most advantaged; Stage: 1 = Localised, 2 = Regional Spread, 3 = Metastatic Diseaobserved among Indigenous compared to non-Indigenous
people (all causes, non-cancer and cancer deaths) and the
survival differential for cancer death remained apparent
when adjusted for confounding factors (age, sex, remote-
ness, stage, socioeconomic status and comorbidities).
When further adjusted for diabetes and/or treatment, the
differential reduced to borderline significance, suggesting
these factors may be associated with lower survival. Des-
pite this, we found that overall Indigenous people who
had treatment fared worse than non-indigenous people
who had treatment, suggesting either the type or quality
of treatment, or other non-treatment factors at play in
overall treatment outcomes.
Survival was worse for Indigenous people in the first
year after diagnosis. After adjustment for stage and co-
morbidities, the survival differential persisted in the first
year but, when adjusted for treatment alone, this diffe-
rence was no longer apparent. Treatment differencesels, of time to death for all cancer diagnosed between
people in Queensland, Australia
(95% CI) aHR* (95% CI)
(1.22, 1.55 ) 1.22 (1.06-1.39)
(1.57, 3.63) 1.95 (1.17, 3.24)
(1.15, 1.48 ) 1.10 (0.96, 1.27)
(1.37, 1.87) 1.33 (1.12, 1.83)
(0.73, 1.33) 1.18 (0.85, 1.65)
(0.76, 1.26) 0.98 (0.77, 1.26)
(0.74, 1.30) 1.03 (0.79 1.36)
(0.76, 1.45) 1.02 (0.72, 1.45)
0, 1, 2+; Accessibility/Remoteness Index of Australia 1 = Highly accessible/
ic Index for Areas): 1 = Most disadvantaged, 2 = Intermediate advantage,
se, 9 = Not sure; Any treatment.
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important contributing factors for the poorer outcomes
immediately after cancer diagnosis among Indigenous
people. Our findings are similar to a recent Queensland
report which included patients treated at public and
private hospitals [2]; Indigenous people were 1.5 times
more likely to die in the first year of diagnosis than non-
Indigenous people, but with excess mortality limited to
the first two years of follow-up after diagnosis. Although
that study was much larger than the present one, it was
limited by a lack of information on cancer stage, comor-
bidities and cancer treatment. Our results, adjusted for
treatment, stage and comorbidities, suggest that dif-
ferences in treatment between the two groups are mainly
responsible for the survival differential in the first year
after a cancer diagnosis.
Misidentification of Indigenous status in Queensland
public hospitals is known to be around 12% [40]. As
Indigenous status was checked in the medical record
review and discrepancies investigated where possible, we
are confident that misclassification in the study sample
is minimal. Matching resulted in little differences in the
distribution of age, sex or cancer type between the two
groups, however, as perfect matching was not possible, it
resulted in the inclusion of a higher proportion of
Indigenous people who lived very remotely and were se-
verely disadvantaged. Of note, 27% of Indigenous people
in this study were from the more remote regions,
whereas 22% of the Indigenous population resident in
Queensland live in these regions [41]. This minimizes
the concern that Indigenous people from remote re-
gions, who potentially have inadequate access to the
health care system, might have been underrepresented
in this study. The chief strength in utilizing data from
the National Death Index (NDI) for vital status is the
virtually complete population coverage. Standardized
and consistent data collection by the NDI ensures that
the death data are of high quality (93.7% sensitivity and
100% specificity for the identification of deaths) [42].
Nevertheless, if a few cases were missed due to reporting
delays to the NDI, they are not likely to be differentially
biased by Indigenous status.
Conclusions
This comprehensive investigation of the patterns of care of
Indigenous people with cancer, confirmed that Indigenous
people had more advanced stage at diagnosis, more co-
morbidities, received less treatment, and had poorer sur-
vival than their non-Indigenous counterparts. In addition,
we found that survival disparity in the first year after diag-
nosis was likely to be related to lack of cancer treatment.
However, Indigenous people receiving cancer treatment
had poorer outcomes overall, despite comparable time
to commencement, duration, and amount of treatmentreceived. We also identified a subset of untreated patients
who might reasonably be considered candidates for cancer
treatment. A greater understanding of the interplay
between overall health, demographic features and cancer,
as well as Indigenous people’s awareness of cancer and
cancer treatment, is therefore required. Indigenous cancer
patients have particular needs that should be considered
when planning cancer care, particularly during the first
year after diagnosis.
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